Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Outpatients > 18 years
Male or female patients. Female patients must have been either post-menopausal for one year, surgically sterile, or using effective contraceptive methods
Patients with essential hypertension, previously treated with an antihypertensive single-drug therapy, either uncontrolled or intolerant.
BP thresholds at visit 1:
BP thresholds at visit 2 (for all patients):
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
506 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal